1,773
Views
24
CrossRef citations to date
0
Altmetric
Clinical Research

The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome

, &
Pages 773-777 | Received 16 Sep 2018, Accepted 25 Dec 2018, Published online: 07 Feb 2019

References

  • Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–1570.
  • Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. J Med Toxicol. 2017;13:71–87.
  • Blumentrath CG, Dohrmann B, Ewald N. Cannabinoid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment. Ger Med Sci. 2017;15:Doc06.
  • Richards JR, Gordon BK, Danielson AR, et al. Pharmacologic treatment of cannabinoid hyperemesis syndrome: a systematic review. Pharmacotherapy. 2017;37:725–734.
  • Witsil JC, Mycyk MB. Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome. Am J Ther. 2017;24:e64–e67.
  • Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol. 2018;56(1):15-24.
  • Moon AM, Buckley SA, Mark NM. Successful Treatment of Cannabinoid Hyperemesis Syndrome with Topical Capsaicin. ACG Case Rep. 2018;5:e3.
  • Hejazi RA, Reddymasu SC, Namin F, et al. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol. 2010;44:18–21.
  • Chang YH, Windish DM. Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc. 2009;84:76–78.
  • Meltzer AC, Mazer-Amirshahi M. For adults with nausea and vomiting in the emergency department, what medications provide rapid relief? Ann Emerg Med. 2016;68:717–718.
  • Apfel CC, Cakmakkaya OS, Frings G, et al. Droperidol has comparable clinical efficacy against both nausea and vomiting. Br J Anaesth. 2009;103:359–363.
  • Richards JR, Schneir AB. Droperidol in the emergency department: is it safe? J Emerg Med. 2003;24:441–447.
  • Calver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings. Br J Clin Pharmacol. 2014;77:880–886.
  • Calver L, Page CB, Downes MA, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med. 2015;66:230–238.e1.
  • Simonetto DA, Oxentenko AS, Herman ML, et al. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87:114–119.
  • United Nations Office on Drugs and Crime. World Drug Report 2016. New York; 2016.
  • Australian Institute of Health and Welfare. National Drug Strategy Household Survey (NDSHS) 2016. In: Welfare AIoHa, editor. 2017.
  • Iacopetti CL, Packer CD. Cannabinoid hyperemesis syndrome: a case report and review of pathophysiology. Clin Med Res. 2014;12:65–67.
  • Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain–gut axis. Gastroenterology. 2016;151:252–266.
  • Darmani NA. Cannabinoid-induced hyperemesis: a conundrum-from clinical recognition to basic science mechanisms. Pharmaceuticals (Basel). 2010;3:2163–2177.
  • Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliat Med. 2012;1:137–142.
  • Hamik A, Peroutka SJ. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24:307–310.
  • Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013;31:1003.e5–1003.e6.
  • Jones JL, Abernathy KE. Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting. Case Rep. 2016;2016:3614053.
  • Calver L, Drinkwater V, Gupta R, et al. Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. Br J Psychiatry. 2015;206:223–228.
  • Richards JR, Dutczak O. Propranolol treatment of cannabinoid hyperemesis syndrome: a case report. J Clin Psychopharmacol. 2017;37:482–484.
  • Dezieck L, Hafez Z, Conicella A, et al. Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. Clin Toxicol. 2017;55(8):908-913.
  • Namin F, Patel J, Lin Z, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil. 2007;19:196–202.
  • Malik Z, Baik D, Schey R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr Gastroenterol Rep. 2015;17:429.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.